News | ASTRO | November 01, 2019

ASTRO supports nomination of Stephen Hahn, M.D., FASTRO, to lead U.S. FDA

Hahn has served on the ASTRO Board of Directors and has broad knowledge as a clinician, researcher, educator and administrative leader

Stephen Hahn, M.D., FASTRO

Stephen Hahn, M.D., FASTRO

November 1, 2019 — The American Society for Radiation Oncology (ASTRO) today expressed strong support for the nomination of radiation oncologist Stephen Hahn, M.D., FASTRO, as Commissioner of the Food and Drug Administration (FDA). Hahn served on the ASTRO Board of Directors from 2014 to 2018. ASTRO urges the Senate to swiftly confirm the nomination announced today by President Donald Trump.

Hahn has broad knowledge as a clinician, researcher, educator and administrative leader, and he previously obtained the rank of commander in the U.S. Public Health Service. He is well-versed on the drug, biologic and device development pipeline, demonstrated by his role in developing multiple medical products. His clinical expertise and training in internal medicine, medical oncology and radiation oncology, as well as his international recognition in treating lung cancer give him the ability to tackle some of the toughest issues faced by the FDA.

Several members of ASTRO's leadership who have worked with Hahn shared their support of his nomination:

"I have known Dr. Hahn for many years and have served with him in numerous capacities.  He possesses the qualities needed to successfully lead the FDA … intelligence, medical and scientific expertise, an engaging style and a clear sense of how to get to the right answer, particularly in complicated situations.”

Theodore L. DeWeese, M.D., FASTRO; Chair, ASTRO Board of Directors 2019-2020; Vice Dean for Clinical Affairs, Sidney Kimmel Professor and Director of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine

"During his tenure on the ASTRO Board, Dr. Hahn always brought insightful questions to our deliberations. He takes the time to listen to all sides before he reaches a decision, which will be important in this new role. I also don't know that I have ever seen anyone who can cover as much ground as he can cover. His depth of knowledge will allow him to accomplish the many tasks ahead as FDA Commissioner.”

Laura I. Thevenot; Chief Executive Officer, ASTRO

"Dr. Hahn is a brilliant physician leader with the highest levels of integrity and problem-solving talent.  With a background in radiation oncology and medical oncology, he is uniquely positioned to advance the crucial work of the FDA.”

Ronald Ennis, M.D., FASTRO; Government Relations Council Chair, ASTRO Board of Directors 2019-2020; Associate Professor of Radiation Oncology, Icahn School of Medicine at Mount Sinai

 

ASTRO previously expressed its support of Dr. Hahn after news reports in September suggested he was being considered for the FDA leadership post. That statement, from then-ASTRO Chair Paul Harari, M.D., FASTRO, noted how Dr. Hahn's clinical experience could translate into success leading the FDA:

"A culture of safety is woven into the fabric of radiation oncology, making Dr. Hahn expertly suited to further FDA’s mission of protecting the public health. At the same time, Dr. Hahn’s experience using some of the most sophisticated medical devices in health care gives him insight and expertise to drive progress for the benefit of patients and consumers."

Paul Harari, M.D., FASTRO; Chair, ASTRO Board of Directors 2018-2019; Jack Fowler Professor and Chairman of Human Oncology, University of Wisconsin School of Medicine and Public Health

 

For more information: www.astro.org

 

Related Content

Esaote, an Italian company among the world leaders in the field of medical diagnostic imaging systems, is the Ducati Team's official partner for the 2020 season
News | Radiology Business | February 14, 2020
February 14, 2020 — Esaote, an Italian company among the world le
Feature | Breast Imaging | February 03, 2020 | By Barbara Smith
Women in the United States have a 1 in 8 (or about 13 percent) lifetime risk of being diagnosed with breast cancer du
HIPAA Regulations

Image courtesy of Carestream 

Feature | Radiology Business | February 03, 2020 | By Carol Amick
According to the U.S.
While electronic medical record systems have helped consolidate most patient data into one location, medical imaging IT systems has proved to be more difficult to replicate by large EMR vendors. This has made room in the market for third-party radiology IT vendors that allow easy integration with the larger EMRs like Epic and Cerner. This image shows Agfa's enterprise imaging system, leveraging its ability to be accessed anywhere with internet connection and pull images from radiology and surgery.

While electronic medical record systems have helped consolidate most patient data into one location, medical imaging IT systems has proved to be more difficult to replicate by large EMR vendors. This has made room in the market for third-party radiology information system vendors that allow easy integration with the larger EMRs like Epic and Cerner. This image shows Agfa's enterprise imaging system, leveraging its ability to be accessed anywhere with an internet connection and able to pull in images from both radiology and surgery. 

Feature | Enterprise Imaging | February 02, 2020 | Steve Holloway
The growing influence and uptake of electronic medical records (EMRs) in healthcare has driven debate over the future
•	Sports Imaging is a unique specialty that allows radiologists to collaborate across the care continuum from detection to treatment

Image courtesy of Carestream Health

Feature | Radiology Business | January 30, 2020 | By Neelesh S. Prakash, M.D.
International Radiology Day (IDoR

Image by Adam Radosavljevic from Pixabay 

News | Radiology Business | January 27, 2020
January 27, 2020 —  Hg, a specialist private equity investor focused on software and service businesses, announced th
Hitachi Healthcare Americas announced that it will create a new dedicated research and development facility within its North American headquarters facility in Twinsburg, Ohio
News | Radiology Business | January 21, 2020
January 21, 2020 — Hitachi Healthcare Americas announced that it will create a new dedicated research and development
Gadolinium based contrast dye in brain MRI

Gadolinium contrast agents (GBCAs) are partly retained in the brain, raising safety concerns, as seen in this MRI.

News | Contrast Media | January 17, 2020
January 17, 2020 — Bracco Diagnostics Inc., the U.
Imaging Technology News (ITN) has been acquired by Wainscot Media
News | Imaging Technology News - ITN | January 14, 2020
January 14, 2020 — Park Ridge, N.J.-based publisher Wainscot Medi...
Partners of Collaborative Imaging experience billing collection improvements of over 25 percent while reducing operating costs by 30 percent

Image courtesy of Philips Healthcare

News | Radiology Business | January 08, 2020
January 8, 2020 — The $18 billion radiology industry continues to face a growing threat of consolidation, resulting i